Apremilast Study for Behçet's disease

apremilast is treatment of bechet syndromeПодробнее

Superior risankizumab efficacy vs. apremilast in systemic-eligible moderate psoriasis.Подробнее

Apremilast Study for Behçet's diseaseПодробнее

Behçet's SyndromeПодробнее

Diagnosis and Management of Behçet’s DiseaseПодробнее

Understanding Behçhet's DiseaseПодробнее

Tc17 cells and NET formation in papulopustular Behcet disease skin lesions, S. Vural et alПодробнее

Apremilast (#6086) - Psoriasis Posters and Abstracts from San DiegoПодробнее

Behcet's Disease: A Canadian Perspective On Awareness, Treatment And ManagementПодробнее

Genetic Factors and Behçet’s disease: A Journey on and off the Silk RoadПодробнее

Cerebral Aneurysms Associated with Behcet’s Disease: A Case Report and Review of the LiteratureПодробнее

Behcet’s DiseaseПодробнее

Exploring the Clinical Understanding of Behcet's Disease, May 28th, 2020Подробнее

Lecture#274, Uvea#15, Behcet's Disease-an International MasterClass by Prof. Ilknur Tugal-TutkunПодробнее

Mark Lebwohl, MD - Apremilast as an Off-Label Therapeutic AgentПодробнее

What you need to know about Behcet's DiseaseПодробнее

Behcet´s Syndrome | Rheumatology Medicine Video Lectures | Medical Student | V-LearningПодробнее

Lecture-120: Introduction to Apremilast in PsoriasisПодробнее

Apremilast effects sustained at 1 year in psoriatic arthritisПодробнее

Professor Rolando Cimaz on Behcet's diseaseПодробнее